AIMS: Some types of monoclonal gammopathies are typified by a very limited availability of aberrant cells. Modern research use high throughput technologies and an integrated approach for detailed characterisation of abnormal cells. This strategy requires relatively high amounts of starting material which cannot be obtained from every diagnosis without causing inconvenience to the patient. The aim of this methodological paper is to reflect our long experience with laboratory work and describe the best protocols for sample collection, sorting and further preprocessing in terms of the available number of cells and intended downstream application in monoclonal gammopathies research. Potential pitfalls are also discussed. METHODS: Comparison and optimisation of freezing and sorting protocols for plasma cells in monoclonal gammopathies, followed by testing of various nucleic acid isolation and amplification techniques to establish a guideline for sample processing in haemato-oncology research. RESULTS: We show the average numbers of aberrant cells that can be obtained from various monoclonal gammopathies (monoclonal gammopathy of undetermined significance/light chain amyloidosis/multiple myeloma (MM)/MM circulating plasma cells/ minimal residual disease MM-10 123/22 846/305 501/68 641/4000 aberrant plasma cells of 48/30/10/16/37×106 bone marrow mononuclear cells) and the expected yield of nucleic acids provided from multiple isolation kits (DNA/RNA yield from 1 to 200×103 cells was 2.14-427/0.12-123 ng). CONCLUSIONS: Tested kits for parallel isolation deliver outputs comparable with kits specialised for just one type of molecule. We also present our positive experience with the whole genome amplification method, which can serve as a very powerful tool to gain complex information from a very small cell population.

Department of Haemato oncology University Hospital Ostrava Ostrava Czech Republic

Department of Haemato oncology University Hospital Ostrava Ostrava Czech Republic Department of Biology and Ecology Faculty of Science University of Ostrava Ostrava Czech Republic

Department of Haemato oncology University Hospital Ostrava Ostrava Czech Republic Faculty of Medicine University of Ostrava Ostrava Czech Republic

Faculty of Medicine University of Ostrava Ostrava Czech Republic Babak Myeloma Group Department of Pathological Physiology Faculty of Medicine Masaryk University Brno Czech Republic

Faculty of Medicine University of Ostrava Ostrava Czech Republic Department of Biology and Ecology Faculty of Science University of Ostrava Ostrava Czech Republic

Faculty of Medicine University of Ostrava Ostrava Czech Republic Department of Experimental Biology Faculty of Science Masaryk University Brno Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc18016696

003      

CZ-PrNML

005      

20180517105912.0

007      

ta

008      

180515s2017 xxk f 000 0|eng||

009      

AR

024    7_

$a 10.1136/jclinpath-2017-204329 $2 doi

035    __

$a (PubMed)28360189

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxk

100    1_

$a Ševčíková, T $u Department of Haemato-oncology, University Hospital Ostrava, Ostrava, Czech Republic. Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.

245    10

$a Biobanking strategy and sample preprocessing for integrative research in monoclonal gammopathies / $c T. Ševčíková, K. Growková, Z. Kufová, J. Filipová, P. Vrublová, T. Jelínek, Z. Kořístek, F. Kryukov, E. Kryukova, R. Hájek,

520    9_

$a AIMS: Some types of monoclonal gammopathies are typified by a very limited availability of aberrant cells. Modern research use high throughput technologies and an integrated approach for detailed characterisation of abnormal cells. This strategy requires relatively high amounts of starting material which cannot be obtained from every diagnosis without causing inconvenience to the patient. The aim of this methodological paper is to reflect our long experience with laboratory work and describe the best protocols for sample collection, sorting and further preprocessing in terms of the available number of cells and intended downstream application in monoclonal gammopathies research. Potential pitfalls are also discussed. METHODS: Comparison and optimisation of freezing and sorting protocols for plasma cells in monoclonal gammopathies, followed by testing of various nucleic acid isolation and amplification techniques to establish a guideline for sample processing in haemato-oncology research. RESULTS: We show the average numbers of aberrant cells that can be obtained from various monoclonal gammopathies (monoclonal gammopathy of undetermined significance/light chain amyloidosis/multiple myeloma (MM)/MM circulating plasma cells/ minimal residual disease MM-10 123/22 846/305 501/68 641/4000 aberrant plasma cells of 48/30/10/16/37×106 bone marrow mononuclear cells) and the expected yield of nucleic acids provided from multiple isolation kits (DNA/RNA yield from 1 to 200×103 cells was 2.14-427/0.12-123 ng). CONCLUSIONS: Tested kits for parallel isolation deliver outputs comparable with kits specialised for just one type of molecule. We also present our positive experience with the whole genome amplification method, which can serve as a very powerful tool to gain complex information from a very small cell population.

650    _2

$a krevní banky $x metody $7 D001771

650    _2

$a konzervace krve $x metody $7 D001793

650    _2

$a odběr vzorku krve $x metody $7 D001800

650    _2

$a kryoprezervace $x metody $7 D015925

650    _2

$a DNA $x izolace a purifikace $7 D004247

650    _2

$a lidé $7 D006801

650    _2

$a paraproteinemie $x krev $7 D010265

650    _2

$a RNA $x izolace a purifikace $7 D012313

650    _2

$a reagenční diagnostické soupravy $7 D011933

655    _2

$a časopisecké články $7 D016428

700    1_

$a Growková, K $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic. Department of Biology and Ecology, Faculty of Science, University of Ostrava, Ostrava, Czech Republic.

700    1_

$a Kufová, Z $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic. Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.

700    1_

$a Filipová, J $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic. Department of Biology and Ecology, Faculty of Science, University of Ostrava, Ostrava, Czech Republic.

700    1_

$a Vrublová, P $u Department of Haemato-oncology, University Hospital Ostrava, Ostrava, Czech Republic.

700    1_

$a Jelínek, T $u Department of Haemato-oncology, University Hospital Ostrava, Ostrava, Czech Republic. Department of Biology and Ecology, Faculty of Science, University of Ostrava, Ostrava, Czech Republic.

700    1_

$a Kořístek, Z $u Department of Haemato-oncology, University Hospital Ostrava, Ostrava, Czech Republic. Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.

700    1_

$a Kryukov, F $u Department of Haemato-oncology, University Hospital Ostrava, Ostrava, Czech Republic.

700    1_

$a Kryukova, E $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic. Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

700    1_

$a Hájek, R $u Department of Haemato-oncology, University Hospital Ostrava, Ostrava, Czech Republic. Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.

773    0_

$w MED00002597 $t Journal of clinical pathology $x 1472-4146 $g Roč. 70, č. 10 (2017), s. 847-853

856    41

$u https://pubmed.ncbi.nlm.nih.gov/28360189 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20180515 $b ABA008

991    __

$a 20180517110048 $b ABA008

999    __

$a ok $b bmc $g 1300320 $s 1013536

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2017 $b 70 $c 10 $d 847-853 $e 20170330 $i 1472-4146 $m Journal of clinical pathology $n J Clin Pathol $x MED00002597

GRA    __

$a NV15-29667A $a NV17-30089A $p MZ0 $p MZ0

GRA    __

$a NV15-29667A $a NV17-30089A $p MZ0 $p MZ0

LZP    __

$a Pubmed-20180515